Application of baishouwu benzophenone in preparation of uric acid reducing medicine

A technology of benzophenone and Baishouwu, which is applied in the field of medicine, can solve problems such as abnormal liver function, accelerated or irregular heartbeat, etc.

Active Publication Date: 2021-05-18
THE KEY LAB OF CHEM FOR NATURAL PROD OF GUIZHOU PROVINCE & CHINESE ACADEMY OF SCI +1
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Compared with the traditional treatment drugs allopurinol and benzbromarone, febuxostat is more effective in lowering uric acid, but it often causes adverse liver function abnormalities, diarrhea, rash, chest pain, syncope or dizziness, rapid or irregular heartbeat, speech Adverse side effects such as difficulty, sudden blurred vision, or headaches such as cardiovascular disease, heart attack, stroke, and heart-related death have been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of baishouwu benzophenone in preparation of uric acid reducing medicine
  • Application of baishouwu benzophenone in preparation of uric acid reducing medicine
  • Application of baishouwu benzophenone in preparation of uric acid reducing medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] Effects of Radix Polygoni Multiflori Benzophenone on Blood Uric Acid Levels in Hyperuricemia Mice Induced by Potassium Oxonate

[0019] Test animals: male KM mice (purchased from Beijing Huafukang Biotechnology Co., Ltd., animal license number: SCXK (Beijing) 2019-0008), 18-22g.

[0020] Operation steps: the mice were divided into random groups, 10 in each group, respectively normal group, model group, each administration group and positive control group (the positive control drug was febuxostat 1.0 mg / kg, each administration group was divided into 10 mL / kg volume intragastric administration of the test drug benzophenone of Radix Polygoni Multiflori 5 times, twice a day with an interval of 8h, wherein the doses of benzophenone of Radix Polygonum multiflorum were 4mg / kg, 8mg / kg and 16mg / kg respectively; positive The treatment of the control group is the same as that of the administration group, except that the drug given is a positive control drug. 1h after the last adm...

Embodiment 2

[0028] Effect of benzophenone of Radix Polygoni Multiflori on blood uric acid level in uric acid-induced hyperuricemia mice

[0029] Test animals: male KM mice (purchased from Beijing Huafukang Biotechnology Co., Ltd., animal license number: SCXK (Beijing) 2019-0008), 18-22g.

[0030] Operation steps: the mice were randomly divided into groups, 10 in each group, which were respectively the normal group, the model group, each administration group and the positive control group (the positive control drug was 25.0mg / kg benzbromarone), and each administration group was divided into 10mL / kg volume intragastric administration of the test drug benzophenone of Radix Polygoni Multiflori 5 times, twice a day with an interval of 8h, wherein the doses of benzophenone of Radix Polygonum multiflorum were 4mg / kg, 8mg / kg and 16mg / kg respectively; The treatment of the positive control group was the same as that of the treatment group, except that the drug given was benzbromarone. 0.5 hours af...

Embodiment 3

[0037] Preliminary Toxicity and Safety Evaluation of Radix Polygonum Benzophenone

[0038] Select 40 healthy ICR mice, half male and half female, weighing 18-22 g, fasting for about 12 hours before administration, and formulating a suspension with 0.5% CMC-Na of Radix Polygoni Multiflori, according to the maximum concentration, The maximum volume of 30mL / kg body weight was administered by intragastric administration, and the intragastric administration was administered once at 9:00 a.m., which was 3.0g / kg / d. After administration, continuous observation was carried out for 14 days, and the animal poisoning and death conditions were recorded. The test results are shown in Table 3 and Table 4.

[0039] Table 3 Effects of Radix Polygoni Multiflori Benzophenone Orally Administered on Body Weight of Mice on Day 0, 7, and 14 (n=10, x±s)

[0040]

[0041]

[0042] Table 4 Coefficients of organ organs (heart, kidney, spleen, liver) of mice (n=10, x±s) 14 days after intragastric ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an application of baishouwu benzophenone in preparation of a uric acid reducing medicine, and belongs to the technical field of medicines. A test result shows that the baishouwu benzophenone can obviously reduce the blood uric acid level of mice with hyperuricemia induced by oteracil potassium, the titer of the baishouwu benzophenone is higher than that of a 1mg / kg dosage group of a positive drug febuxostat, and the difference has significant statistical significance; and meanwhile, the blood uric acid level of the mice with uric acid induced hyperuricemia can be remarkably reduced by using 8.0 mg / kg and 16.0 mg / kg dosage groups of the baishouwu benzophenone, certain dose dependence exists, compared with the positive drug, the titer of the baishouwu benzophenone is higher than that of a 25mg / kg dosage group of the positive drug benzbromarone, and the difference has significant statistical significance. The baishouwu benzophenone provided by the invention achieves a good uric acid reducing effect in the application of preparing the uric acid reducing medicine, and is safe and free of sequelae.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to the application of Radix Polygonum benzophenone in the preparation of uric acid-lowering medicine. Background technique [0002] Gout is a heterogeneous disease characterized by hyperuricemia (HUA) caused by metabolic disorders of purine substances and / or decreased uric acid excretion. HUA is not only the biochemical basis of gout, but also an independent risk factor for metabolic syndrome, diabetes, hypertension, myocardial infarction, stroke, cardiovascular disease, coronary heart disease, all-cause death, metabolic disease, and chronic kidney disease. The prevalence of HUA is also on the rise worldwide, becoming a worldwide public health problem that seriously threatens human health. [0003] At present, the representative drug that inhibits uric acid synthesis is allopurinol, and the representative drug that promotes uric acid excretion is benzbromarone. Patients will ha...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/122A61P19/06
CPCA61K31/122A61P19/06
Inventor 黄烈军郝小江李玲牛艳芬高丽辉杨娟苑春茂顾玮金军蹇军友胡占兴
Owner THE KEY LAB OF CHEM FOR NATURAL PROD OF GUIZHOU PROVINCE & CHINESE ACADEMY OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap